Cancer immunotherapy and cardiovascular side-effects: from treatment modalities to the use of the preventive effect of antihypertensive drugs
Rahim F. Gozin S. Karim S.H. Qumar A.B. Doostali K. Balday I.
2025Open Exploration Publishing Inc
Exploration of Immunology
2025#5
Cancer treatment regimens are significantly more intricate than commonly perceived. Nonetheless, both immunotherapy and chemotherapy may produce adverse consequences. Immunotherapy represents a significant advancement in the battle against cancer; nonetheless, it is not devoid of challenges. This research elucidates the mechanisms underlying immunotherapy-induced cardiovascular damage, highlighting the significant role of immune regulators, such as soluble urokinase plasminogen activator receptor (suPAR), in inducing vascular leakage. We also examine the role of matrix metalloproteinase (MMP14/15) in this process, and antigens associated with cardiovascular illness and malignancies, including native proteins, mutated tumor antigens, and viral components. Besides, we studied predictive biomarkers, such as circulating T-cell populations associated with the probability of myocarditis. We discuss treatment approaches and strategies to mitigate these issues, particularly through the use of antihypertensive medications to reduce their impact. Losartan alters the tumor microenvironment (TME) to improve immunotherapy. It restores immune effector cells in triple-negative breast cancer (TNBC), overcomes resistance in unresponsive tumors, and modifies TMEs’ immune system suppression in ovarian cancer and melanoma. It is important to note that its effects differ by cancer kind. It may promote fibrosarcoma tumor growth and improve cholangiocarcinoma treatment. This shows that losartan’s dangers in cancer treatment should be carefully considered and that more research is needed. This suggests that there must be careful consideration of the potential risks associated with losartan use in cancer treatment and underscores the requirement for additional research on this topic. This study may enhance our comprehension and management of cardiovascular adverse effects in cancer immunotherapy by integrating novel insights on immunological predictors and vascular dysfunction. Experts assert that oncology programs must provide and promote continuous monitoring of cardiac health for breast cancer patients. To mitigate the risk of cardiovascular disease in this demographic, comprehensive patient care must be administered.
cancer , cardiovascular diseases (CVD) , immune checkpoint inhibitors (ICIs) , immunotherapy , side-effects
Text of the article Перейти на текст статьи
Department of Internal Medicine, Osh State University, Osh, 723500, Kyrgyzstan
Department of Medical Biology, Faculty of Medicine, Kocaeli University, Kocaeli, 41001, Turkey
Faculty of Medicine, Istanbul Atlas University, Istanbul, 34010, Turkey
Chemical Weapon Victim’s Hospital, Halabja General Directorate of Health, Halabja, 46018, Iraq
Department of Health Policy and Management, Asfendiyarov Kazakh National Medical University, Almaty, 050004, Kazakhstan
Heart and Vein Department, Dr Doostali Heart Care Clinic, Tehran, 11369, Iran
Department of Nursing, Asfendiyarov Kazakh National Medical University, Almaty, 050004, Kazakhstan
Department of Internal Medicine
Department of Medical Biology
Faculty of Medicine
Chemical Weapon Victim’s Hospital
Department of Health Policy and Management
Heart and Vein Department
Department of Nursing
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026